KP 106

Drug Profile

KP 106

Alternative Names: KP106

Latest Information Update: 26 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KemPharm
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Aug 2013 Discontinued - Phase-I for Attention-deficit hyperactivity disorder in USA (PO)
  • 30 Aug 2011 KP 106 is available for licensing as of 30 Aug 2011.
  • 30 Aug 2011 KemPharm reports its intention to file for approval in USA in the first half of 2013 for Attention-deficit hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top